{"id":"NCT00885079","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Confirmatory Study of OPC-12759 Ophthalmic Suspension","officialTitle":"Confirmatory Study of OPC-12759 Ophthalmic Suspension in Dry Eye Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2010-03","completion":"2010-04","firstPosted":"2009-04-21","resultsPosted":"2013-12-12","lastUpdate":"2013-12-12"},"enrollment":188,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndromes"],"interventions":[{"type":"DRUG","name":"OPC-12759 Ophthalmic suspension","otherNames":[]},{"type":"DRUG","name":"Hyalein Mini Ophthalmic solution","otherNames":[]}],"arms":[{"label":"Rebamipide","type":"EXPERIMENTAL"},{"label":"Hyaluronate","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to verify whether OPC-12759 ophthalmic suspension is effective compared with active control in dry eye patients.","primaryOutcome":{"measure":"Change in Fluorescein Corneal Staining (FCS) Score From Baseline","timeFrame":"Baseline, Weeks4","effectByArm":[{"arm":"Rebamipide","deltaMin":-3.7,"sd":0.3},{"arm":"Hyaluronate","deltaMin":-2.9,"sd":0.2}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":93},"commonTop":["Dysgeusia (bitter taste)","Eye pruritus","Conjunctival haemorrhage","Eye pain","Nasopharyngitis"]}}